These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34085994)

  • 21. Teprotumumab and hearing loss: hear the warnings.
    Chern A; Gudis DA; Dagi Glass LR
    Orbit; 2021 Aug; 40(4):355-356. PubMed ID: 33622158
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hearing abnormalities in patients treated with teprotumumab.
    Brant JA; Kikkawa DO; Smith TJ
    Nat Rev Endocrinol; 2024 Jul; 20(7):381-382. PubMed ID: 38740893
    [No Abstract]   [Full Text] [Related]  

  • 24. Teprotumumab Related Hearing Loss: A Large-Scale Analysis and Review of Voluntarily Reported Patient Complaints to the Food and Drug Administration (FDA).
    McGwin G; Owsley C; Vicinanzo MG
    Ophthalmic Plast Reconstr Surg; 2024 May; ():. PubMed ID: 38771914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results.
    Kay-Rivest E; Belinsky I; Kozlova A; Byrd E; McMenomey SO; Jethanamest D
    Otolaryngol Head Neck Surg; 2023 May; 168(5):1164-1169. PubMed ID: 36939482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
    Chu M; Sung J; Song M; Song A; Song J
    J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe Hyperglycemia with Teprotumumab for Treatment of Thyroid Eye Disease.
    Cottom S; Barrientez B; Melson A
    Case Rep Ophthalmol; 2024; 15(1):246-249. PubMed ID: 38504670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease.
    Shah K; Charitou M
    AACE Clin Case Rep; 2022; 8(4):148-149. PubMed ID: 35959086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.
    Safo MB; Silkiss RZ
    Am J Ophthalmol Case Rep; 2021 Jun; 22():101069. PubMed ID: 33817409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
    Douglas RS; Dailey R; Subramanian PS; Barbesino G; Ugradar S; Batten R; Qadeer RA; Cameron C
    JAMA Ophthalmol; 2022 Apr; 140(4):328-335. PubMed ID: 35175308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
    Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
    Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
    Chen KW; Phelps PO
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of asymmetric thyroid eye disease with teprotumumab.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
    Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teprotumumab for chronic thyroid eye disease.
    Ozzello DJ; Dallalzadeh LO; Liu CY
    Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic.
    Yee MD; McCarthy J; Quinn B; Surani A
    WMJ; 2023 May; 122(2):134-137. PubMed ID: 37141481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report.
    Meijer AJM; van den Heuvel-Eibrink MM; Brooks B; Am Zehnhoff-Dinnesen AG; Knight KR; Freyer DR; Chang KW; Hero B; Papadakis V; Frazier AL; Blattmann C; Windsor R; Morland B; Bouffet E; Rutkowski S; Tytgat GAM; Geller JI; Hunter LL; Sung L; Calaminus G; Carleton BC; Helleman HW; Foster JH; Kruger M; Cohn RJ; Landier W; van Grotel M; Brock PR; Hoetink AE; Rajput KM;
    JAMA Oncol; 2021 Oct; 7(10):1550-1558. PubMed ID: 34383016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.